Prophylactic cryoprecipitate in congenital afibrinogenemia
Related Experiment Videos
R C Rodriguez1, G R Buchanan, M S Clanton
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063.
Insights
Prophylactic cryoprecipitate infusions effectively prevented serious hemorrhage in two siblings with congenital afibrinogenemia. This fibrinogen replacement therapy showed no adverse effects, offering a viable treatment for this rare bleeding disorder.
Area of Science:
- Hematology
- Pediatrics
- Rare Diseases
Background:
- Congenital afibrinogenemia is a rare inherited bleeding disorder characterized by a complete absence of fibrinogen.
- Managing this condition in early childhood often involves preventing serious hemorrhage.
- Previous treatment strategies may have limitations or associated risks.
Observation:
- Two siblings diagnosed with congenital afibrinogenemia were treated prophylactically.
- Cryoprecipitate, a blood product rich in fibrinogen, was administered regularly.
- Infusions were given every 7-10 days for extended periods (15 and 24 months).
Findings:
- Prophylactic cryoprecipitate infusions nearly completely prevented serious hemorrhage during the treatment period.
- No adverse side effects were observed in either sibling during cryoprecipitate administration.
- The long half-life of fibrinogen makes cryoprecipitate a practical prophylactic option.
Implications:
- Cryoprecipitate prophylaxis is a safe and effective strategy for managing congenital afibrinogenemia in children.
- This approach offers a promising method to prevent bleeding complications in affected individuals.
- Consideration of cryoprecipitate prophylaxis should be extended to other patients with this rare disorder.
Abstract:
Two siblings with congenital afibrinogenemia received prophylactic infusions of cryoprecipitate in order to prevent serious hemorrhage during early childhood. Three bags (units) of this fibrinogen-containing blood product were administered every 7-10 days for 15 months in one case and 24 months in the other. Hemorrhage was nearly completely prevented during the period of prophylaxis. Side effects from cryoprecipitate were not observed. Prophylactic infusion of cryoprecipitate, made practical by the relatively long half-life of fibrinogen, should be considered in other patients with this disorder.